Luye Pharma Group Ltd.
LYPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $7 | $9 | $10 | $11 |
| - Cash | $7 | $5 | $3 | $6 |
| + Debt | $12 | $10 | $9 | $8 |
| Enterprise Value | $12 | $15 | $16 | $14 |
| Revenue | $3 | $3 | $3 | $3 |
| % Growth | 6.5% | -2.9% | -5.1% | – |
| Gross Profit | $2 | $2 | $2 | $2 |
| % Margin | 67.8% | 65.8% | 67.6% | 69.8% |
| EBITDA | $1 | $1 | $1 | $1 |
| % Margin | 31.5% | 41.9% | 30.6% | 31.8% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 9.8% | 2.8% | 12.6% | 11.8% |
| EPS Diluted | 0.083 | -0.083 | 0.1 | 0.102 |
| % Growth | 200.8% | -182.5% | -1.8% | – |
| Operating Cash Flow | $2 | $1 | -$0 | $1 |
| Capital Expenditures | $0 | -$2 | $0 | -$1 |
| Free Cash Flow | $2 | -$1 | -$0 | $0 |